Masimo Corporation Files Fiscal Year 2025 10-K/A Amendment: Key Details for Investors

Overview

Masimo Corporation (Nasdaq: MASI), a leading global medical technology company, has filed Amendment No. 1 to its Annual Report on Form 10-K (10-K/A) for the fiscal year ended January 3, 2026. This amendment provides the comprehensive Part III information previously omitted from the original filing, including updates on the Board of Directors, executive compensation, corporate governance, and additional disclosures that are crucial for investors.

Key Highlights from the 10-K/A Filing

• Inclusion of Omitted Information: This amendment fills in required details for Part III (Items 10, 11, 12, 13, and 14) of Form 10-K, which were not included in the company’s initial annual report. The omitted information pertains to directors, executive compensation, ownership, related transactions, and principal accounting fees. The company clarifies that it will not be filing a separate proxy statement with this information, opting instead for this amendment.
• No Financial Statements Restated or Amended: The amendment does not include or modify financial statements or disclosures related to internal controls over financial reporting. There is no Section 906 certification included, as no financial statements are being filed with this amendment.
• Updated Board and Governance Information: The amendment provides a detailed breakdown of the current Board of Directors, committee memberships (Audit, Talent and Compensation, Nominating/Compliance/Corporate Governance, and Business Risk and Review), and identifies the current Chairperson and committee financial experts.
• Executive Compensation Policies: The amendment outlines Masimo’s executive compensation philosophy, emphasizing a performance-based culture. The majority of executive compensation for the CEO, CFO, and CCO is at-risk and tied to company performance, with a clear mix of base salary, annual incentives, and long-term equity incentives (stock options, RSUs, and PSUs). The company highlights a robust set of compensation policies and practices, including a clawback policy, no hedging or pledging (except for rare exceptions), no guaranteed bonuses, rigorous performance metrics, and multi-year vesting schedules.
• Performance Metrics and Results:
  • Annual Incentives: Adjusted Revenue, Adjusted Non-GAAP Earnings Per Share, and Adjusted True Incremental Contract Value are the key annual performance metrics. For 2025, the targets were set at or above the high end of the company’s guidance range, with adjustments to exclude foreign currency fluctuations and share repurchases not reflected in targets.
  • Long-Term Incentives (PSUs): Performance Share Units are based on three-year cumulative Adjusted Revenue, three-year cumulative Adjusted Non-GAAP Operating Income, and a three-year Relative TSR Modifier (comparing Masimo’s total shareholder return to S&P Healthcare Equipment Select Index constituents). The TSR modifier can adjust payouts by up to 25% and is capped at 250% of the target grant opportunity.
• Corporate Governance and Compliance: The company affirms compliance with all Section 16(a) filings, with only minor administrative delays in reporting by several directors and officers. All issues have been subsequently corrected. Masimo also reiterates its adherence to a Code of Business Conduct and Ethics, with no material changes to director nomination procedures or insider trading policies.
• Shareholder Information:
  • Market Value: As of June 28, 2025, Masimo’s public float was approximately \$3.9 billion.
  • Outstanding Shares: As of January 31, 2026, there were 52,192,538 shares of common stock outstanding.
  • Listing: Masimo’s common stock is listed on The Nasdaq Stock Market LLC under the trading symbol MASI.
• Issuer Status: Masimo is classified as a “well-known seasoned issuer” and a “large accelerated filer.” The company is not considered a shell company and has met all electronic filing requirements, including those for interactive data files.

Potentially Price-Sensitive Information

• Disclosure of Executive Compensation Structure: Investors may view the continued focus on pay-for-performance, rigorous performance metrics, and the absence of guaranteed bonuses or tax gross-ups as a positive corporate governance signal, potentially supporting long-term shareholder value.
• Performance Targets Set High: The fact that performance targets are set at or above the high end of guidance may reassure investors about management’s confidence, but also signals the challenge of earning incentive payouts, which may impact executive retention and future results.
• Governance and Compliance Transparency: The prompt correction of minor Section 16(a) filing delays and transparent disclosure of insider trading and ethics policies may enhance investor confidence in the board and management.
• Clarity on Omitted Information: By filing this amendment, the company reduces uncertainty regarding previously omitted governance and compensation disclosures, which may remove overhang risks and improve transparency for investors.

Conclusion

Masimo Corporation’s 10-K/A filing delivers significant transparency to investors regarding executive compensation, governance, and compliance. While there are no restatements or substantial changes to financial results, the company’s continued emphasis on performance-based pay, strong governance practices, and timely disclosure of administrative matters could be viewed positively by the market. However, investors should note the high performance hurdles set for management and the lack of guaranteed bonuses, which may impact executive incentives going forward.

Disclaimer

The above is a summary prepared for informational purposes only and does not constitute investment advice. Investors are encouraged to review the full 10-K/A amendment and consult with their financial advisors before making any investment decisions. The information is based on the company’s SEC filings and may be updated or amended in future disclosures.

View MASIMO CORP Historical chart here